

▼ This medicinal product is subject to additional monitoring **in Australia**. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at <https://www.tga.gov.au/reporting-problems>.

AUSTRALIAN PRODUCT INFORMATION

BIMZELX® (BIMEKIZUMAB) 160 MG/ML INJECTION

1 NAME OF THE MEDICINE

Bimekizumab

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Bimzelx 160 mg solution for injection

Each pre-filled syringe or pen contains 160 mg bimekizumab in 1 ml.

Bimzelx 320 mg solution for injection

Each pre-filled syringe or pen contains 320 mg bimekizumab in 2 ml.

Bimekizumab is a recombinant humanized full-length monoclonal antibody of the IgG1 sub-class, expressed in a genetically engineered Chinese hamster ovary cell line.

For the full list of excipients, see Section 6.1 List of Excipients.

3 PHARMACEUTICAL FORM

Solution for injection.

The solution is clear to slightly opalescent and, colourless to pale brownish-yellow.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Plaque Psoriasis

Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Psoriatic arthritis

Bimzelx is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response to or who have been intolerant to previous disease modifying antirheumatic drug (DMARD) therapy.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA)

Bimzelx is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI) who have had an inadequate response to or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)

Bimzelx is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Hidradenitis suppurativa (HS)

Bimzelx is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic HS therapy.

4.2 DOSE AND METHOD OF ADMINISTRATION

The Instructions for Use included as a pack insert must be followed carefully.

Plaque Psoriasis

The recommended dose of Bimzelx for adult patients with plaque psoriasis is 320 mg (given as 2 subcutaneous injections of 160 mg or 1 subcutaneous injection of 320 mg) at Week 0, 4, 8, 12, 16 and every 8 weeks thereafter.

Psoriatic arthritis

The recommended dose of Bimzelx for adult patients with active psoriatic arthritis is 160 mg (given as one subcutaneous injection of 160 mg) every 4 weeks.

For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, the use of the dose applicable to plaque psoriasis may be considered [i.e. 320 mg (given as 2 subcutaneous injections of 160 mg each or 1 subcutaneous injection of 320 mg) at Week 0, 4, 8, 12, 16 and every 8 weeks thereafter]. After 16 weeks, regular assessment of efficacy is recommended and if a sufficient clinical response in joints cannot be maintained, a switch to 160 mg every 4 weeks can be considered.

Axial spondyloarthritis (nr-axSpA and AS)

The recommended dose of Bimzelx for adult patients with active axial spondyloarthritis is 160 mg (given as one subcutaneous injection of 160 mg) every 4 weeks.

Hidradenitis suppurativa

The recommended dose of Bimzelx for adult patients with hidradenitis suppurativa is 320 mg (given as 2 subcutaneous injections of 160 mg or 1 subcutaneous injection of 320 mg) every 4 weeks.

If more rapid disease control is desired and after consideration of the individual patient risks and benefits a Bimzelx dose for adult patients with hidradenitis suppurativa of 320mg (given as 2 subcutaneous injections of 160 mg or 1 subcutaneous injection of 320 mg) every 2 weeks up to 16 weeks and every 4 weeks thereafter may be considered.

Method of administration

Bimzelx is administered by subcutaneous injection. A 320 mg dose can be given as 2 subcutaneous injections of 160 mg or 1 subcutaneous injection of 320 mg.

Suitable areas for injection include thigh, abdomen and upper arm. Injection sites should be rotated and injections should not be given into psoriasis plaques or areas where the skin is tender, bruised, erythematous, or indurated.

Bimzelx is for single use in one patient only. Discard any residue.

Special populations

Overweight patients (plaque psoriasis)

For some patients with plaque psoriasis (including psoriatic arthritis with coexistent moderate to severe psoriasis) and a body weight \geq 120 kg, 320 mg every 4 weeks after Week 16 may be considered (see Section 5.1 Pharmacodynamic Properties, Clinical trials).

Elderly population

No dose adjustment is required (see Section 5.2 Pharmacokinetic Properties).

Renal and hepatic impairment

Bimzelx has not been studied in these patient populations. Dose adjustments are not considered necessary based on pharmacokinetics (see Section 5.2 Pharmacokinetic Properties). No specific PK studies using Bimzelx have been pursued in patients with underlying impaired hepatic function.

Paediatric population

The safety and efficacy of Bimzelx in children and adolescents below the age of 18 years has not been established. No data are available.

4.3 CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients (see Section 6.1 List of Excipients).

Live vaccines should not be given in patients treated with Bimzelx. No data are available on the response to live vaccines.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Infections

Bimzelx increases the risk of infections such as upper respiratory tract infections and mucocutaneous candidiasis (mostly oral, less frequent vulvovaginal, oesophageal) (see section 4.8 Adverse effects (Undesirable effects)).

Caution should be exercised when considering the use of Bimzelx in patients with a chronic infection or a history of recurrent infection. Treatment with Bimzelx should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with Bimzelx should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection and/or fungal infection occur. If a patient develops a clinically important infection or is not responding to standard therapy, the patient should be closely monitored and Bimzelx should not be administered until the infection resolves.

Pre-treatment evaluation for tuberculosis (TB)

No increased susceptibility to tuberculosis was reported from clinical studies. Prior to initiating treatment with Bimzelx, patients should be evaluated for TB infection. Bimzelx should not be given in patients with active TB. Patients receiving Bimzelx should be monitored for signs and symptoms of

active TB. Anti-TB therapy should be considered prior to initiating Bimzelx in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Inflammatory bowel disease

Cases of new onset or exacerbations of inflammatory bowel disease have been reported during bimekizumab treatment. Caution should be exercised when prescribing Bimzelx to patients with inflammatory bowel disease. Patients should be monitored closely.

Hypersensitivity

If a serious hypersensitivity reaction occurs, administration of Bimzelx should be discontinued immediately and appropriate therapy initiated.

Vaccinations

Prior to initiating therapy with Bimzelx, consider completion of all appropriate immunizations according to current immunization guidelines.

Patients treated with Bimzelx may receive inactivated or non-live vaccinations. Healthy individuals who received a single 320 mg dose of Bimzelx two weeks prior to vaccination with an inactivated seasonal influenza vaccine had similar antibody responses compared to individuals who did not receive Bimzelx prior to vaccination.

Use in hepatic impairment

Bimzelx has not been studied in these patient populations. Dose adjustments are not considered necessary based on pharmacokinetics (see Section 5.2 Pharmacokinetic Properties).

Use in renal impairment

Bimzelx has not been studied in these patient populations. Dose adjustments are not considered necessary based on pharmacokinetics (see Section 5.2 Pharmacokinetic Properties).

Use in the elderly

Based on population pharmacokinetic analysis with a limited number of elderly patients (n = 110 for age \geq 65 years and n = 14 for age \geq 75 years), apparent clearance (CL/F) in elderly patients and patients less than 65 years of age was similar. No dose adjustment is required.

Paediatric use

The safety and efficacy of Bimzelx in children and adolescents below the age of 18 years has not been established. No data are available.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

No CYP450 interaction studies have been performed in humans. There is no direct evidence for the role of IL-17A or IL-17F in the expression of CYP450 enzymes. Given that (1) bimekizumab, as an IgG1K mAb, is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG and (2) formation of some CYP450 enzymes which is suppressed by elevated levels of cytokines during inflammation (as in psoriasis), will be reversed by inflammatory suppressors, like IL-17A and IL-17F inhibitor bimekizumab, the resultant outcome will be a normalisation of CYP450 levels/activity. Extrapolation of the latter means that drugs metabolized by the CYP450 system may be co-administered with bimekizumab. However, monitoring of

therapeutic plasma level and clinical effect of drugs with narrow therapeutic index (e.g. warfarin) metabolized via CYP450 system should be considered.

Population pharmacokinetic (PK) data analyses indicated that concomitant administration of conventional disease modifying antirheumatic drugs (cDMARDs) including methotrexate or prior exposure to biologic have no clinically relevant impact on the clearance of bimekizumab.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on Fertility

The effect of bimekizumab on human fertility has not been evaluated. In animal studies, bimekizumab did not indicate harmful effects with respect to fertility as assessed by a lack of effects on reproductive organs, menstrual cycles or sperm in sexually mature cynomolgus monkeys that received bimekizumab for 26 weeks at a weekly SC dose of 200 mg/kg (dose resulting in 84 times the human exposure at 320 mg every 2 weeks based on AUC). The monkeys were not mated to evaluate functional fertility.

Use in Pregnancy (Category C)

There are no adequate and well controlled studies in pregnant women to establish the safety of Bimzelx during pregnancy. Based on the mechanism of action of bimekizumab, the theoretical risk that use during pregnancy may affect neonatal immunity cannot be excluded. In an enhanced pre/postnatal development study in the cynomolgus monkey, bimekizumab showed no effects on gestation, parturition, infant survival, fetal or postnatal development when administered throughout organogenesis until parturition at a maternal dose of 50 mg/kg SC weekly resulting in 12 times the human exposure at 320 mg every 2 weeks based on AUC. At birth, serum bimekizumab concentrations in infant monkeys were comparable to those of mothers indicating placental transfer of bimekizumab. Bimzelx should be used in pregnancy only if the benefits clearly outweigh the potential risks.

Use in Lactation

It is not known whether bimekizumab is excreted in human milk or absorbed systemically after ingestion. As immunoglobulins can be excreted in human milk, caution should be exercised when Bimzelx is administered to a woman who is breast-feeding and a decision on whether to discontinue breast-feeding during treatment should be made.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Bimekizumab is not anticipated to have any influence on the ability to drive and use machines.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

A total of 5862 patients have been treated with bimekizumab in blinded and open-label clinical studies in plaque psoriasis, psoriatic arthritis, axial spondyloarthritis (nr-axSpA and AS) and hidradenitis suppurativa representing 11468.7 patient-years of exposure. Of these, over 4660 patients were exposed to bimekizumab for at least one year.

Overall, the safety profile of bimekizumab is consistent across all indications.

Plaque Psoriasis

The most frequently reported adverse drug reactions (ADRs) were upper respiratory tract infections (most frequently nasopharyngitis) and oral candidiasis.

Table 1: Adverse Drug Reactions Occurring in Greater Than 1% of Subjects on BIMZELX through Week 16 in BE-VIVID and BE-READY (Plaque Psoriasis)

Adverse Drug Reactions	BIMZELX 320 mg every four weeks N = 670 n (%)	Placebo N = 169 n (%)
Upper respiratory tract infections ^a	97 (14.5)	23 (13.6)
Oral Candidiasis	49 (7.3)	0
Headache	22 (3.3)	0
Injection Site Reactions ^b	17 (2.5)	0
Vulvovaginal candidiasis ^c	3 (1.6)	0
Acne	8 (1.2)	0
Oropharyngeal candidiasis	8 (1.2)	0
Folliculitis	8 (1.2)	0
Gastroenteritis	8 (1.2)	0
Tinea pedis	8 (1.2)	0
Fatigue	7 (1.0)	0
Oral herpes	7 (1.0)	0

^a Includes nasopharyngitis, pharyngitis, upper respiratory tract infection, rhinitis, sinusitis, tonsillitis, and peritonsillar abscess.

^b Includes injection site erythema, injection site reaction, injection site oedema, injection site pain, and injection site swelling.

^c In females only

Psoriatic Arthritis

Table 2: Treatment Emergent Adverse Events regardless of causality reported by ≥2% of subjects through Week 16 in BE-OPTIMAL and BE-COMPLETE (Psoriatic Arthritis)

TEAEs	Bimekizumab N=698 n (%)	Placebo N=413 n (%)
Upper respiratory tract infections ^a	77 (11.0)	34 (8.2)
Headache	25 (3.6)	7 (1.7)
Diarrhoea	19 (2.7)	8 (1.9)
Oral candidiasis	16 (2.3)	0
Hypertension	15 (2.1)	14 (3.4)
Urinary tract infection	14 (2.0)	7 (1.7)
Arthralgia	8 (1.1)	9 (2.2)
Psoriatic arthropathy	4 (0.6)	9 (2.2)

^a Includes nasopharyngitis and upper respiratory tract infection

Table 3: Adverse Drug Reactions Occurring in Greater Than 1% of Subjects on BIMZELX through Week 16 in BE-OPTIMAL and BE-COMPLETE (Psoriatic Arthritis)

Adverse Drug Reactions	BIMZELX 160 mg every four weeks N = 698 n (%)	Placebo N = 413 n (%)
Upper respiratory tract infections ^a	99 (14.2)	41 (9.9)
Headache	25 (3.6)	7 (1.7)
Diarrhoea	19 (2.7)	8 (1.9)
Oral candidiasis	16 (2.3)	0
Urinary tract infection	14 (2.0)	7 (1.7)
Fatigue	8 (1.1)	6 (1.5)
Neutropenia	8 (1.1)	0
Dry skin	7 (1.0)	1 (0.2)

^a Includes nasopharyngitis, upper respiratory tract infection, pharyngitis, sinusitis and rhinitis

Axial spondyloarthritis (axSpA)

Table 4: Treatment Emergent Adverse Events regardless of causality reported by $\geq 2\%$ subjects through Week 16 in BE-MOBILE 1 and BE-MOBILE 2 (AS and nr-axSpA)

TEAEs	BKZ N=349 n (%)	Placebo N=237 n (%)
Upper respiratory tract infections ^a	53 (15.2)	31 (13.1)
Oral candidiasis	13 (3.7)	0
Headache	12 (3.4)	7 (3.0)
Diarrhoea	10 (2.9)	3 (1.3)
Injection site pain	8 (2.3)	3 (1.3)
Rash	8 (2.3)	1 (0.4)
Uveitis	2 (0.6)	8 (3.4)

^a Includes nasopharyngitis, pharyngitis, rhinitis and upper respiratory tract infection

Table 5: Adverse Drug Reactions Occurring in Greater Than 1% of Subjects on BIMZELX through Week 16 in BE-MOBILE 1 and BE-MOBILE 2 (AS and nr-axSpA)

Adverse Drug Reactions	BIMZELX 160 mg every four weeks N = 349 n (%)	Placebo N = 237 n (%)
Upper respiratory tract infections ^a	57 (16.3)	34 (14.3)
Vulvovaginal mycotic infection ^b	6 (5.2)	0
Oral candidiasis	13 (3.7)	0
Headache	12 (3.4)	7 (3.0)
Injection site pain	8 (2.3)	3 (1.3)
Rash	8 (2.3)	1 (0.4)
Conjunctivitis	4 (1.1)	3 (1.3)
Fatigue	4 (1.1)	2 (0.8)
Folliculitis	4 (1.1)	2 (0.8)
Gastroenteritis	4 (1.1)	2 (0.8)
Oral herpes	4 (1.1)	0

^a Includes nasopharyngitis, upper respiratory tract infection, pharyngitis, rhinitis, tonsillitis and sinusitis

^b In females only

Hidradenitis Suppurativa

Table 6: Treatment Emergent Adverse Events occurring $\geq 2\%$ of Study Participants on BIMZELX 320mg Q2W treatment group and greater than Placebo in - Initial Treatment Period in BE HEARD I and BE HEARD II

TEAEs	Bimzelx 320mg Q4W N=285 n (%)	Bimzelx 320mg Q2W N=576 n (%)	Placebo N=146 n (%)
Upper respiratory tract infections ^a	23 (8.1)	53 (9.2)	7 (4.8)
Oral candidiasis	7 (2.5)	41 (7.1)	0
Headache	15 (5.3)	40 (6.9)	10 (6.8)
Injection site reactions ^b	13 (4.6)	37 (6.4)	2 (1.4)
Diarrhoea	17 (6.0)	36 (6.3)	7 (4.8)
Corona virus infection	5 (1.8)	20 (3.5)	2 (1.4)
Pyrexia	8 (2.8)	19 (3.3)	2 (1.4)
Fatigue	8 (2.8)	16 (2.8)	3 (2.1)
Folliculitis	8 (2.8)	16 (2.8)	0

Oropharyngeal pain	4 (1.4)	15 (2.6)	2 (1.4)
Eczema	5 (1.8)	14 (2.4)	2 (1.4)
Abdominal pain	4 (1.4)	13 (2.3)	2 (1.4)
Pruritus	6 (2.1)	13 (2.3)	1 (0.7)
Dermatitis contact	4 (1.4)	12 (2.1)	0

^a Includes nasopharyngitis, pharyngitis, upper respiratory tract infection, tonsillitis, sinusitis, rhinitis, acute sinusitis, laryngitis, pharyngeal abscess

^b Includes injection site reaction, injection site pain, injection site erythema, injection site swelling, injection site pruritus, injection site bruising, injection site urticaria, injection site rash, injection site haemorrhage and injection site discolouration

Adverse drug reactions occurring in greater than 1% of subjects on Bimzelx and at a higher rate than in the placebo group through week 16 in the HS clinical trials that are not listed in the table above are constipation, asthenia, otitis externa, vulvovaginal mycotic infection, tinea pedis, myalgia, acne, seborrhoeic dermatitis, urticaria.

Other adverse reactions (< 1%)

Adverse drug reactions that occurred in < 1% but > 0.1% of subjects in the Bimzelx group and at a higher rate than in the placebo group through Week 16 were, conjunctivitis, tinea infection, herpes simplex, dyshidrotic eczema, intertrigo, dermatitis, otitis media, cutaneous and other mucosal candidiasis (including oesophageal).

Description of selected adverse reactions

Infections

In the placebo-controlled period of Phase III clinical studies in plaque psoriasis, infections were reported in 36.0% of patients treated with bimekizumab for up to 16 weeks compared with 22.5% of patients treated with placebo. The majority of infections consisted of non-serious mild to moderate upper respiratory tract infections such as nasopharyngitis. There were higher rates of oral and oropharyngeal candidiasis in patients treated with bimekizumab consistent with the mechanism of action (7.3% and 1.2% respectively compared to 0% for placebo-treated patients). In the PS0015 study over the 48-week comparator controlled period, a higher incidence rate of oral candidiasis was observed in BKZ (19.3%) compared to secukinumab (3.0%) in PSO patients. The vast majority of cases were non-serious, mild or moderate in severity, and did not require treatment discontinuation.

Serious infections occurred in 0.3% of patients treated with bimekizumab and 0% treated with placebo.

Over the entire treatment period of Phase III studies in plaque psoriasis, infections were reported in 63.2% of patients treated with bimekizumab (120.4 per 100 patient-years). Serious infections were reported in 1.5% of patients treated with bimekizumab (1.6 per 100 patient-years) (see section 4.4).

Infection rates observed in PsA, axSpA (nr-axSpA and AS) and HS Phase III clinical studies were similar to those observed in plaque psoriasis.

In the placebo-controlled period, oral and oropharyngeal candidiasis rates in patients treated with bimekizumab were 2.3% and 0% respectively in PsA, 3.7% and 0.3% respectively in axSpA and 7.1% and 0% respectively in HS compared to 0% with placebo.

Neutropenia

Neutropenia was observed with bimekizumab in phase III clinical studies in plaque psoriasis. In the 16 weeks placebo-controlled period neutropenia grade 3/4 were observed at the same frequency of 0.6% in patients receiving bimekizumab or placebo. Over the entire treatment period of Phase III studies, neutropenia grade 3/4 were observed in 1 % of patients treated with bimekizumab.

The frequency of neutropenia in PsA, axSpA (nr-axSpA and AS) and HS clinical studies was similar to that observed in plaque psoriasis studies.

Most cases of neutropenia were transient and did not require treatment discontinuation. No serious infections were associated with neutropenia.

Hepatic transaminases

Psoriatic arthritis

During the placebo-controlled period, increased incidence of elevated hepatic transaminases was observed in psoriatic arthritis patients treated with bimekizumab compared to placebo.

Increase >3x upper limit of normal (ULN) and >5xULN in hepatic transaminase levels were observed in the bimekizumab group (>3-5xULN ALT: 0.9%, AST: 0.3%; >5xULN ALT: 0.1%, AST: 0.4%), while no elevated ALT and AST was seen in the placebo group.

Elevations (mainly >3xULN) in ALT and AST were also observed during the long-term treatment with bimekizumab.

The majority of ALT or AST elevations had confounding factors or alternative explanations, were transient and resolved.

Axial spondyloarthritis

During the placebo-controlled period, hepatic transaminases elevations were observed in axial spondyloarthritis patients at a similar uncommon incidence in the bimekizumab and placebo group (>3-5xULN ALT: 0.3% vs. 0.8%, AST: 0.9% vs. 0.4%; >5xULN ALT: 0.6% vs. 0.4%, AST: 0.6% vs. 0.4%, respectively in the bimekizumab and placebo group).

Elevations (mainly >3xULN) in ALT and AST were also observed during the long-term treatment with bimekizumab.

The majority of ALT or AST elevations had confounding factors or alternative explanations, were transient and resolved.

Hidradenitis suppurativa

During the placebo-controlled period, increased incidence of elevated hepatic transaminases was observed in hidradenitis suppurativa patients treated with bimekizumab compared to placebo.

Increases >3x ULN and >5xULN in hepatic transaminase levels were observed in the bimekizumab 320mg Q2W group (>3-5xULN ALT: 0.3%, AST: 0.9%; >5xULN ALT: 0.2%, AST: 0.5%), and in the bimekizumab 320mg Q4W group (>3-5xULN ALT:0%, AST:0.7%; >5xULN ALT or AST: 0%) while no >3xULN elevations in ALT and AST were seen in the placebo group.

Elevations (mainly >3xULN) in AST and ALT were also observed during long-term treatment with bimekizumab.

The majority of AST or ALT elevations had confounding factors or alternative explanations, were transient and resolved.

One study participant with history of hepatic enzyme increased of unknown etiology experienced a >10xULN rise in ALT and AST 14 days after starting bimekizumab 320mg Q2W. AST, ALT and GGT started to rise within 28 days prior to administration of the first dose. The event, reported as “potential DILI”, led to study discontinuation as per protocol withdrawal criteria and resolved in <1 month.

Immunogenicity

As with all therapeutic proteins, there is the potential for immunogenicity with bimekizumab. The detection of anti-drug antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of anti-drug antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to bimekizumab with the incidence of antibodies to other products may be misleading.

Plaque psoriasis

Approximately 45% of plaque psoriasis patients treated with bimekizumab up to 56 weeks at the recommended dosing regimen (320 mg every 4 weeks up to Week 16 and 320 mg every 8 weeks thereafter) developed anti-drug antibodies. Of the patients who developed anti-drug antibodies, approximately 34% (16% of all patients treated with bimekizumab) had antibodies that were classified as neutralizing.

Psoriatic arthritis

Approximately 31% of patients with psoriatic arthritis treated with bimekizumab at the recommended dosing regimen (160 mg every 4 weeks) up to 16 weeks had anti-drug antibodies. Of the patients with anti-drug antibodies, about 33% (10% of all patients treated with bimekizumab) had antibodies that were classified as neutralizing. By Week 52, approximately 47% of patients with PsA in the BE OPTIMAL study treated with bimekizumab at the recommended dosing regimen (160 mg every 4 weeks) had anti-drug antibodies. Of the patients in the BE OPTIMAL study with anti-drug antibodies, about 38% (18% of all patients treated with bimekizumab) had antibodies that were classified as neutralizing.

Axial spondyloarthritis

nr-axSpA - Approximately 57% of patients with nr-axSpA treated with bimekizumab up to 52 weeks at the recommended dosing regimen (160 mg every 4 weeks) had anti-drug antibodies. Of the patients with anti-drug antibodies, approximately 44% (25% of all patients treated with bimekizumab) had antibodies that were classified as neutralizing.

AS -Approximately 44% of patients with AS treated with bimekizumab up to 52 weeks at the recommended dosing regimen (160 mg every 4 weeks) had anti-drug antibodies. Of the patients with anti-drug antibodies, approximately 44% (20% of all patients treated with bimekizumab) had antibodies that were classified as neutralizing.

Hidradenitis suppurativa

Approximately 54% of HS patients treated with bimekizumab up to 48 weeks at the recommended dosing regimen (320 mg every 2 weeks up to Week 16 and 320 mg every 4 weeks thereafter) had or developed anti-drug antibodies. Of the patients who had or developed anti-drug antibodies, approximately 63% (37% of all patients treated with bimekizumab 320mg every 2 weeks up to Week 16 and 320mg every 4 weeks thereafter) had antibodies that were classified as neutralizing. Across all indications, no clinically meaningful impact on clinical response or safety profile was associated with anti-bimekizumab antibodies development.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <http://www.tga.gov.au/reporting-problems>.

4.9 OVERDOSE

Single doses of 640 mg intravenously or 640 mg subcutaneously, followed by 320 mg subcutaneously every two weeks for five doses have been administered in clinical studies without dose-limiting toxicity. In the event of overdose, it is recommended that the patient be monitored for any signs and symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Bimekizumab is a humanised IgG1/ κ monoclonal antibody with two identical antigen binding regions that bind and neutralise IL-17A, IL-17F and IL-17AF cytokines. Levels of IL-17A and IL-17F are elevated in several immune mediated inflammatory diseases and drive chronic inflammation and damage across multiple tissues. IL-17A and IL-17F cooperate and / or synergise with other inflammatory cytokines to induce inflammation. IL-17F is produced in significant amounts by innate immune cells. This production can be independent of IL-23. In lesional HS tissue, both IL-17A and IL-17F are highly expressed compared to non-HS tissues. In human *in vitro* models, dual neutralisation of both IL-17A and IL-17F with bimekizumab suppresses the expression of inflammation related genes and proteins, inhibits the migration of inflammatory cells and pathological osteogenesis to a greater extent than inhibition of IL-17A alone.

Pharmacodynamic effects

No formal pharmacodynamic (PD) studies have been conducted with bimekizumab.

Clinical trials

Psoriasis - Phase 3 pivotal studies

The safety and efficacy of bimekizumab was evaluated in 1480 patients with moderate to severe plaque psoriasis in three Phase III multicenter, randomized, placebo and/or active comparator-controlled studies. Patients were at least 18 years of age, had a Psoriasis Area and Severity Index (PASI) score ≥ 12 and Body Surface Area (BSA) affected by PSO $\geq 10\%$, an Investigators Global Assessment (IGA) score ≥ 3 on a 5-point scale and were candidates for systemic psoriasis therapy and/or phototherapy. The efficacy and safety of bimekizumab were evaluated versus placebo and ustekinumab (BE VIVID – PS0009), versus placebo (BE READY – PS0013) and versus adalimumab (BE SURE - PS0008).

The BE VIVID study evaluated 567 patients for 52 weeks where patients were randomized to receive either bimekizumab 320 mg every 4 weeks, ustekinumab (45 mg or 90 mg, depending on patient

weight, at baseline and Week 4 and then every 12 weeks), or placebo for an initial 16 weeks followed by bimekizumab 320 mg every 4 weeks.

The BE READY study evaluated 435 patients for 56 weeks. Patients were randomized to receive bimekizumab 320 mg every 4 weeks or placebo. At Week 16, patients who achieved a PASI 90 response entered the 40-week randomized withdrawal period. Patients initially randomized to bimekizumab 320 mg every 4 weeks were re-randomized to either bimekizumab 320 mg every 4 weeks or bimekizumab 320 mg every 8 weeks or placebo (i.e. withdrawal of bimekizumab). Patients initially randomized to placebo continued to receive placebo provided they were PASI 90 responders. Patients who did not achieve a PASI 90 response at Week 16 entered an open-label escape arm and received bimekizumab 320 mg every 4 weeks for 12 weeks. Patients who relapsed (did not achieve PASI 75 response) during the randomized withdrawal period also entered the 12-week escape arm.

The BE SURE study evaluated 478 patients for 56 weeks. Patients were randomized to receive either bimekizumab 320 mg every 4 weeks through Week 56, bimekizumab 320 mg every 4 weeks through Week 16 followed by bimekizumab 320 mg every 8 weeks through Week 56 or adalimumab as per labeling recommendation through Week 24 followed by bimekizumab 320 mg every 4 weeks through Week 56.

Baseline characteristics were consistent across all 3 studies. Among those, the median baseline BSA was 20%, the median baseline PASI score was 18 and the baseline IGA score was severe in 33% of patients. The median baseline scores for Patient Symptoms Diary (PSD) pain, itch and scaling items ranged between 6 and 7 on a 0-10 points scale and the median baseline Dermatology Life Quality Index (DLQI) total score was 9.

Across all 3 studies, 38% of patients had received a prior biologic therapy; 23% had received at least one anti-IL17 agent and 13% had received at least one TNF-antagonist. Twenty-two percent were naïve to any systemic therapy (including non-biologic and biologic) and 39% of patients had received prior phototherapy or chemotherapy.

The efficacy of bimekizumab was evaluated with respect to impact on skin disease overall, specific body locations (scalp, nails and hand and foot), patient reported symptoms and impact on quality of life. The two co-primary end-points in all 3 studies were the proportion of patients who achieved 1) a PASI 90 response and 2) an IGA “clear or almost clear” (IGA 0/1 with at least two points improvement from baseline) response at Week 16. PASI 100, IGA 0 response at Week 16 and PASI 75 response at Week 4 were key secondary endpoints in all 3 studies.

Skin disease overall

Treatment with bimekizumab resulted in significant improvement in the measures of disease activity compared to placebo, ustekinumab or adalimumab at Week 16. The key efficacy results are shown in Table 7.

Table 7: Summary of clinical responses in BE VIVID, BE READY and BE SURE

	BE VIVID			BE READY		BE SURE	
	Placebo (N= 83) n (%)	BKZ 320 mg Q4W (N= 321) n (%)	Ustekinumab (N=163) n (%)	Placebo (N= 86) n (%)	BKZ 320 mg Q4W (N= 349) n (%)	BKZ 320 mg Q4W (N= 319) n (%)	Adalimumab (N= 159) n (%)
PASI 100 Week 16	0 (0.0)	188 (58.6) ^a	34 (20.9)	1 (1.2)	238 (68.2) ^a	194 (60.8) ^a	38 (23.9)
PASI 90 Week 16	4 (4.8)	273 (85.0) ^{a, b}	81 (49.7)	1 (1.2)	317 (90.8) ^a	275 (86.2) ^a	75 (47.2)
PASI 75 Week 4 Week 16	2 (2.4) 6 (7.2)	247 (76.9) ^{a, b} 296 (92.2)	25 (15.3) 119 (73.0)	1 (1.2) 2 (2.3)	265 (75.9) ^a 333 (95.4)	244 (76.5) ^a 295 (92.5)	50 (31.4) 110 (69.2)
IGA 0 Week 16	0 (0.0)	188 (58.6) ^a	36 (22.1)	1 (1.2)	243 (69.6) ^a	197 (61.8)	39 (24.5)
IGA 0/1 Week 16	4 (4.8)	270 (84.1) ^{a, b}	87 (53.4)	1 (1.2)	323 (92.6) ^a	272 (85.3) ^a	91 (57.2)
Absolute PASI ≤ 2 Week 16	3 (3.6)	273 (85.0)	84 (51.5)	1 (1.2)	315 (90.3)	280 (87.8)	86 (54.1)
PSD Pain (N) Week 16	(N=54) 9 (16.7)	(N=229) 177 (77.3) ^a	(N=107) 73 (68.2)	(N=67) 6 (9.0)	(N=255) 201 (78.8) ^a	(N=252) 180 (71.4)	(N=108) 63 (58.3)
PSD Itch (N) Week 16	(N=61) 8 (13.1)	(N=244) 187 (76.6) ^a	(N=117) 77 (65.8)	(N=72) 4 (5.6)	(N=278) 210 (75.5) ^a	(N=262) 179 (68.3)	(N=116) 58 (50.0)
PSD Scaling (N) Week 16	(N=63) 8 (12.7)	(N=246) 193 (78.5) ^a	(N=116) 69 (59.5)	(N=70) 4 (5.7)	(N=286) 223 (78.0) ^a	(N=261) 185 (70.9)	(N= 119) 59 (49.6)

BKZ 320 mg Q4W= bimekizumab every 4 weeks. Non-Responder Imputation (NRI) is used.

IGA 0/1 response was defined as Clear (0) or Almost Clear (1) with at least a 2-category improvement from Baseline at Week 16. IGA 0 response was defined as Clear (0) with at least a 2-category improvement from Baseline at Week 16.


PSD is Patient Symptoms Diary. PSD response is defined as a change from baseline to Week 16 ≥ to a pre-specified threshold (1.98, 2.39, and 2.86 respectively for pain itch and scaling). A pooled supportive analysis of PSD responses in BE VIVID and BE READY using a more stringent threshold for response definition, i.e. a change from baseline to Week 16 ≥ 4, in the 3 PSD item scores (pain, itch, scaling) provided similar results with response rates of 72.2%, 67.0% and 75.8% in the bimekizumab treatment group versus rates of 5.2%, 5.3% and 5.8% in the placebo group.

^{a)} p<0.001 versus placebo (BE VIVID and BE READY), versus adalimumab (BE SURE), adjusted for multiplicity.

^{b)} p<0.001 versus ustekinumab (BE VIVID), adjusted for multiplicity.

Bimekizumab was associated with a rapid onset of efficacy. In BE VIVID, at Week 2 and Week 4, PASI 90 response rates were significantly higher for bimekizumab-treated patients (12.1% and 43.6% respectively) compared to placebo (1.2% and 2.4% respectively) and ustekinumab (1.2% and 3.1% respectively).

Figure 1: PASI 90 responder rates over time in BE VIVID




BKZ=bimekizumab; Uste=ustekinumab. NRI is used.

In the BE VIVID study, at Week 52, bimekizumab-treated patients achieved significantly higher response rates than the ustekinumab-treated patients on the endpoints of PASI 90 (81.6% bimekizumab vs 55.8% ustekinumab, $p < 0.001$), IGA 0/1 (77.9% bimekizumab vs 60.7% ustekinumab, $p < 0.001$) and PASI 100 (64.2% bimekizumab vs 38.0% ustekinumab).

In the BE SURE study at Week 24, a significantly higher percentage of patients treated with bimekizumab achieved a PASI 90 and an IGA 0/1 responses as compared with adalimumab (85.6% and 86.5% respectively vs 51.6% and 57.9% respectively, $p < 0.001$). Among the 65 adalimumab non-responders at Week 24 (< PASI 90), 78.5% achieved a PASI 90 response after 16 weeks of treatment with bimekizumab. No new safety findings were observed in patients who switched from adalimumab to bimekizumab. At Week 56, 70.2% of bimekizumab-treated patients achieved a PASI 100 response.

Figure 2: PASI 90 responder rates over time in BE SURE



BKZ 320 mg Q4W = bimekizumab every 4 weeks; BKZ 320 mg Q8W = bimekizumab every 8 weeks; ADA= adalimumab. Note: Only patients who received bimekizumab at Week 24 or later are included. Patients in the BKZ Q4W/Q8W group switched from Q4W to Q8W dosing at Week 16. Patients in the ADA/BKZ 320 mg Q4W group switched from ADA to BKZ Q4W at Week 24. NRI is used.

The efficacy of bimekizumab was demonstrated regardless of age, gender, race, disease duration, body weight, PASI baseline severity and previous treatment with a biologic. Bimekizumab was efficacious in prior biologic exposed patients, including anti-TNF / anti IL-17 and in systemic treatment-naïve patients.

Based on population PK/ PD analysis in patients with moderate to severe plaque psoriasis, some patients with higher body weight (≥ 120 kg) benefit from Bimzelx 320 mg every four weeks after the initial 16 weeks of treatment.

Across the entire bimekizumab Phase 3 psoriasis program, including 3 pivotal Phase 3 studies (BE SURE, BE VIVID, and BE READY) and the Phase 3b study (BE RADIANT – PS0015), a total of 1362 study participants were randomized to treatment with bimekizumab. Of these, 116 (8.5%) presented with a body weight ≥ 120 kg at Baseline.

A post-hoc analyses of efficacy for the subgroups of study participants weighing < 120 kg or ≥ 120 kg in the Initial Treatment Period (with bimekizumab 320mg Q4W dosing from Week 0 to Week 16), pooled across all psoriasis Phase 3/3b studies is shown below:

Table 8: Week 16 efficacy outcomes by weight

Key outcomes	BE SURE, BE VIVID, BE READY and BE RADIANT		
	Weight <120kg N=1246	Weight ≥120kg N=116	BKZ Total N=1362
PASI 90	87.7%	78.4%	86.9%
IGA 0/1	87.7%	78.4%	86.9%
PASI 100	64.3%	42.2%	62.4%
IGA 0	65.4%	42.2%	63.4%

BKZ = bimekizumab; IGA= Investigator's Global Assessment; PASI 90=90% or greater improvement in the Psoriasis Area and Severity Index; PASI 100= 100% improvement in the Psoriasis Area and Severity Index

Although the number of subjects in the ≥120 kg group is low, the data demonstrate that response rates were lower in patients weighing more than 120kg compared with patients who weighed less and, represents a clinical correlation with the reduction in exposure as predicted by the PK/PD modelling.

The difference with bimekizumab 320mg Q4W dosing between patients <120kg and patients ≥120kg weights, however, is only numerical [9.3% for both PASI 90 & IGA 0/1]. There was no statistical analysis.

Based on the pooled analysis, greater increases in PASI 100 and IGA 0 were seen in the patients ≥120kg beyond Week 16 with Q4W maintenance dosing compared to Q8W maintenance dosing. No statistical comparison was performed. Thus, it can be stated that increasing the dosing frequency in heavier patients has not been shown to result in greater statistically significant efficacy but may be used to increase plasma concentrations of bimekizumab in heavier patients.

Maintenance of response

Table 9: Maintenance of responses at Week 52 in responders at Week 16*


PASI 100		PASI 90		IGA 0/1		Absolute PASI ≤ 2	
BKZ 320mg Q4W/Q4W (N=355) n (%)	BKZ 320mg Q4W/Q8W (N=182) n (%)	BKZ 320mg Q4W/Q4W (N=516) n (%)	BKZ 320mg Q4W/Q8W (N=237) n (%)	BKZ 320mg Q4W/Q4W (N=511) n (%)	BKZ 320mg Q4W/Q8W (N=234) n (%)	BKZ 320mg Q4W/Q4W (N=511) n (%)	BKZ 320mg Q4W/Q8W (N= 238) n (%)
295 (83.1)	161 (88.5)	464 (89.9)	214 (90.3)	447 (87.5)	214 (91.5)	460 (90.0)	215 (90.3)

* Integrated analysis of BE VIVID, BE READY and BE SURE. NRI is used.

BKZ 320 mg Q4W/Q4W: bimekizumab 320 mg every 4 weeks followed by bimekizumab 320mg every 4 weeks from Week 16. BKZ 320 mg Q4W/Q8W: bimekizumab 320 mg every 4 weeks followed by bimekizumab 320mg every 8 weeks from Week 16.

Durability of PASI 90 response (after bimekizumab discontinuation)

Figure 3: PASI 90 responder rates over time – Randomized withdrawal period in BE READY



NRI is used.

In BE READY, for PASI 90 responders at Week 16 who were re-randomized to placebo and withdrawn from bimekizumab, the median time to relapse, defined as loss of PASI 75, was approximately 28 weeks (32 weeks after the last bimekizumab dose). Among these patients, 88.1% regained a PASI 90 response within 12 weeks of restarting treatment with bimekizumab 320 mg every 4 weeks.

Specific body locations

Significant improvements were observed in psoriasis involving the scalp, nails and hands and feet in patients treated with bimekizumab at Week 16 (see Table 10).

Table 10: Specific body location responses in BE VIVID, BE READY and BE SURE at Week 16

	BE VIVID			BE READY		BE SURE	
	Placebo	BKZ 320 mg Q4W	Ustekinumab	Placebo	BKZ 320 mg Q4W	BKZ 320 mg Q4W	Adalimumab
Scalp IGA (N) ^a	(72)	(285)	(146)	(74)	(310)	(296)	(138)
Scalp IGA 0/1, n (%)	11 (15.3)	240 (84.2) ^b	103 (70.5)	5 (6.8)	286 (92.3) ^b	256 (86.5)	93 (67.4)
pp-IGA (N) ^a	(29)	(105)	(47)	(31)	(97)	(90)	(34)
pp-IGA 0/1, n (%)	7 (24.1)	85 (81.0)	39 (83.0)	10 (32.3)	91 (93.8)	75 (83.3)	24 (70.6)
mNAPSI 100 (N) ^a	(51)	(194)	(109)	(50)	(210)	(181)	(95)
mNAPSI 100, n (%)	4 (7.8)	57 (29.4)	15 (13.8)	3 (6.0)	73 (34.8)	54 (29.8)	21 (22.1)

NRI is used.

a) Include only patients with a scalp Investigator Global Assessment (IGA) of 2 or greater, a palmoplantar IGA of 2 or greater and a modified Nail Psoriasis and Severity Index (mNAPSI) score > 0 at baseline. Scalp IGA 0/1 and pp-IGA 0/1 responses were defined as Clear (0) or Almost Clear (1) with ≥2 category improvement relative to Baseline.

b) p<0.001 versus placebo, adjusted for multiplicity.

Scalp IGA and palmoplantar IGA responses were maintained through Week 52/56. Nail psoriasis continued to improve beyond Week 16. In BE VIVID, at Week 52, 60.3% of patients treated with bimekizumab 320 mg every 4 weeks achieved complete nail clearance (mNAPSI 100). In BE READY, at Week 56, 67.7% and 69.8% of Week 16 PASI 90 responders achieved complete nail clearance with bimekizumab 320 mg every 8 weeks and bimekizumab 320 mg every 4 weeks respectively.

Health-related Quality of Life / Patient reported outcomes

Across all 3 studies, a greater proportion of patients treated with bimekizumab experienced no impact of psoriasis on their quality of life as measured by the Dermatology Life Quality Index (DLQI) compared to placebo and active comparator-treated patients at Week 16 (Table 11).

Table 11: Quality of life in study BE VIVID, BE READY and BE SURE at Week 16

	BE VIVID			BE READY		BE SURE	
	Placebo (N= 83)	BKZ 320 mg Q4W (N= 321)	Ustekinumab (N= 163)	Placebo (N= 86)	BKZ 320 mg Q4W (N= 349)	BKZ 320 mg Q4W (N= 319)	Adalimumab (N= 159)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
DLQI 0/1^a	10 (12.0)	216 (67.3)	69 (42.3)	5 (5.8)	264 (75.6)	201 (63.0)	74 (46.5)

^a) DLQI absolute score of 0 or 1 indicates no impact of the disease on health-related quality of life. NRI is used.

DLQI 0/1 responses continued to increase beyond Week 16 and then were maintained through Week 52 / 56. In BE VIVID, DLQI 0/1 response rate at Week 52 was higher in bimekizumab-treated patients (74.5%) compared with ustekinumab-treated patients (63.2%).

Psoriasis - Phase 3 Open Label Extension study

Patients who completed one of the pivotal phase 3 studies (‘feeder studies’) could enter a 144-week open-label extension study (OLE) (PS0014) to assess the long-term safety and efficacy of bimekizumab.

From Week 1 to Week 144 of the OLE, patients who were treated with bimekizumab 320 mg every 8 weeks (BKZ 320 mg Q8W) during the feeder study and who achieved PASI90 at the end of the feeder study continued to receive bimekizumab 320 mg Q8W.

Improvements achieved with bimekizumab across the spectrum of efficacy endpoints including PASI90, PASI100, IGA 0/I, PASI <2, and DLQI 0/1 in the feeder studies were maintained through an additional 144 weeks of open-label treatment (in total, 4 years of treatment) (Table 12).

Table 12: Response rates for patients who were PASI 90 responders at the end of the feeder study, and who were treated in PS0014 with BKZ 320 mg Q8W through Week 144 (OC*)

<u>Endpoint (n/Nsub (%))</u>		BKZ 320mg Q8W N=384
PASI90	Baseline**	381/384 (99.2)
	Week 144	298/314 (94.9)
IGA 0/1	Baseline**	372/384 (96.9)
	Week 144	295/314 (93.9)

* OC = Observed Cases

**Baseline = Baseline of the OLE

Psoriasis - Phase 3b Head to Head study

The efficacy and safety of bimekizumab were also evaluated in a double-blind study compared with secukinumab, an IL-17A inhibitor, (BE RADIANT - PS0015). Patients were randomized to receive bimekizumab (N=373, 320mg at Week 0, 4, 8, 12 and 16 (Q4W) followed by 320mg every 4 weeks (Q4W/Q4W) or 320 mg every 8 weeks (Q4W/Q8W)) or secukinumab (N=370, 300 mg at Weeks 0,1, 2, 3, 4 followed by 300 mg every 4 weeks). Baseline characteristics were consistent with a population of moderate to severe plaque psoriasis patients with a median BSA of 19% and a median PASI score of 18.

Bimekizumab-treated patients achieved significantly higher response rates compared to secukinumab for the primary endpoint of PASI100 (complete skin clearance) at Week 16. Significantly higher response rates were also achieved with bimekizumab for the secondary endpoints of PASI 100 at Week 48 (for both Q4W/Q4W and Q4W/Q8W regimens) and PASI75 at Week 4. Comparative PASI response rates are presented in Table 13. Bimekizumab was associated with a rapid onset of efficacy. Differences in response rates between bimekizumab and secukinumab-treated patients were noted as early as Week 1 for PASI 75 (7.2% and 1.4% respectively) and as early as Week 2 for PASI 90 (7.5% and 2.4% respectively).

Table 13: PASI response rates from BE RADIANT - bimekizumab versus secukinumab


	Week 4		Week 16		Week 48 ^{a)}		
	BKZ 320 mg Q4W (N=373) n (%)	secukinumab (N=370) n (%)	BKZ 320 mg Q4W (N=373) n (%)	secukinumab (N=370) n (%)	BKZ 320 mg Q4W/Q4W (N=147) n (%)	BKZ 320 mg Q4W/Q8W (N=215) n (%)	secukinumab (N=354) n (%)
PASI 100	52 (13.9)	23 (6.2)	230 (61.7)*	181 (48.9)	108 (73.5)*	142 (66.0)*	171 (48.3)
PASI 90	134 (35.9)	65 (17.6)	319 (85.5)	275 (74.3)	126 (85.7)	186 (86.5)	261 (73.7)
PASI 75	265 (71.0)*	175 (47.3)	348 (93.3)	337 (91.1)	134 (91.2)	196 (91.2)	301 (85.0)
Absolute PASI<2	151 (40.6)	75 (20.3)	318 (85.3)	283 (76.5)	127 (86.4)	186 (86.5)	269 (76.0)

^{a)} Data are from the Maintenance Set consisting of participants who received at least one dose of study treatment at Week 16 or later

*p<0.001 versus secukinumab, adjusted for multiplicity. NRI is used.

Bimekizumab and secukinumab PASI 100 response rates through Week 48 are presented in Figure 4.

Figure 4: PASI 100 response rate over time in BE RADIANT



NRI is used. Maintenance Set consisting of participants who received at least one dose of study treatment at Week 16 or later

Psoriatic arthritis

The safety and efficacy of bimekizumab were evaluated in 1112 adult patients (at least 18 years of age) with active psoriatic arthritis (PsA) in two multicenter, randomized, double-blind, placebo-controlled studies (PA0010 - BE OPTIMAL and PA0011- BE COMPLETE). The BE OPTIMAL study included an active reference treatment arm (adalimumab, N=140). For both studies, patients had a diagnosis of active psoriatic arthritis for at least 6 months based on the Classification Criteria for Psoriatic Arthritis (CASPAR) and had active disease with tender joint count (TJC) ≥ 3 and swollen joint count (SJC) ≥ 3 . Patients had a diagnosis of PsA for a median of 4.6 years. Patients with each subtype of PsA were enrolled in these studies, including polyarticular symmetric arthritis, oligoarticular asymmetric arthritis, distal interphalangeal joint predominant, spondylitis predominant and arthritis mutilans. At baseline, 55.9% of patients had $\geq 3\%$ Body Surface Area (BSA) with active plaque psoriasis with 10.4% of patients having moderate to severe plaque psoriasis. 31.9% and 12.3% had enthesitis and dactylitis at baseline respectively. The primary efficacy endpoint in both studies was the American College of Rheumatology (ACR) 50 response at Week 16.

The BE OPTIMAL study evaluated 852 patients not previously exposed to any biologic disease-modifying anti-rheumatic drug (bDMARD) for the treatment of psoriatic arthritis or psoriasis. Patients were randomized (3:2:1) to receive bimekizumab 160 mg every 4 weeks up to Week 52 or placebo up to Week 16 followed by bimekizumab 160 mg every 4 weeks up to Week 52 or an active reference treatment (adalimumab 40 mg every 2 weeks) up to Week 52. In this study, 78.3% of patients had received prior treatment with ≥ 1 conventional DMARDs (cDMARDs) and 21.7% of patients had no prior treatment with cDMARDs. At baseline, 58.2% of patients were receiving concomitant methotrexate (MTX), 11.3% were receiving concomitant cDMARDs other than MTX, and 30.5% were receiving no cDMARDs.

The BE COMPLETE study evaluated 400 patients with an inadequate response (lack of efficacy) or intolerance to treatment with 1 or 2 tumor necrosis factor alpha inhibitors (anti-TNF α – IR) for either psoriatic arthritis or psoriasis. Patients were randomized (2:1) to receive bimekizumab 160 mg every 4

weeks or placebo up to Week 16. At baseline, 42.5% of patients were receiving concomitant MTX, 8.0% were receiving concomitant cDMARDs other than MTX, and 49.5% were receiving no cDMARDs.

Clinical response

In bDMARD-naïve patients (BE OPTIMAL) and anti-TNF α IR patients (BE COMPLETE) treatment with bimekizumab resulted in significant improvement in signs and symptoms and measures of disease activity compared to placebo at Week 16, with similar response rates seen in both patient populations (see Table 14). Clinical responses were sustained up to Week 52 in BE OPTIMAL as assessed by ACR 20, ACR 50, ACR 70, MDA, PASI 90, PASI 100 and ACR 50 / PASI 100.

Table 14: Clinical response in study BE OPTIMAL and BE COMPLETE

	BE OPTIMAL (bDMARD-naïves)			BE COMPLETE (anti TNF α -IRs)		
	Placebo (N=281) n (%)	BKZ 160 mg Q4W (N=431) n (%)	Difference from placebo (95% CI) ^e	Placebo (N=133) n (%)	BKZ 160 mg Q4W (N=267) n (%)	Difference from placebo (95% CI) ^e
ACR 20						
Week 16 (secondary) ^f	67 (23.8)	268 (62.2)	38.3 (31.4, 45.3)	21 (15.8)	179 (67.0)	51.2 (42.1, 60.4)
Week 24		282 (65.4)				
Week 52		307 (71.2)				
ACR 50						
Week 16 (primary)	28 (10.0)	189 (43.9)*	33.9 (27.4, 40.4)	9 (6.8)	116 (43.4)*	36.7 (27.7, 45.7)
Week 24		196 (45.5)				
Week 52		235 (54.5)				
ACR 70						
Week 16 (secondary) ^f	12 (4.3)	105 (24.4)	20.1 (14.7, 25.5)	1 (0.8)	71 (26.6)	25.8 (18.2, 33.5)
Week 24		126 (29.2)				
Week 52		169 (39.2)				
MDA^(a)						
Week 16 (secondary)	37 (13.2)	194 (45.0)*	31.8 (25.2, 38.5)	8 (6.0)	118 (44.2)*	38.2 (29.2, 47.2)
Week 24		209 (48.5)				
Week 52		237 (55.0)				
Patients with $\geq 3\%$ BSA	(N=140)	(N=217)		(N=88)	(N=176)	
PASI 90						
Week 16 (secondary)	4 (2.9)	133 (61.3)*	58.4 (49.9, 66.9)	6 (6.8)	121 (68.8)*	61.9 (51.5, 72.4)
Week 24		158 (72.8)				
Week 52		155 (71.4)				
PASI 100						
Week 16	3 (2.1)	103 (47.5)	45.3 (36.7, 54.0)	4 (4.5)	103 (58.5)	54.0 (43.1, 64.8)
Week 24		122 (56.2)				
Week 52		132 (60.8)				
ACR 50 / PASI 100						
Week 16	0	60 (27.6)	NC (NC, NC)	1 (1.1)	59 (33.5)	32.4 (22.3, 42.5)
Week 24		68 (31.3)				
Week 52		102 (47.0)				
Patients with LDI>0^(b)	(N=47)	(N=90)				
Dactylitis free state^(b)						
Week 16 (secondary)	24 (51.1)	68 (75.6)***	24.5 (8.4, 40.6)			
Patients with LEI>0^(c)	(N=106)	(N=249)				
Enthesitis free state^(c)						
Week 16 (secondary)	37 (34.9)	124 (49.8)**	14.9 (3.7, 26.1)			
Patients with SPARCC>0^(d)	(N=141)	(N=288)				
Enthesitis free state^(d)						
Week 16 (secondary)	44 (31.2)	139 (48.3)	17.1 (7.2, 26.9)			

BKZ 160 mg Q4W= bimekizumab 160 mg every 4 weeks. CI= confidence interval. NC=Not calculable

^(a) A patient was classified as achieving Minimal Disease Activity (MDA) when meeting 5 of the 7 following criteria: tender joint count ≤ 1 ; swollen joint count ≤ 1 ; Psoriasis Activity and Severity Index ≤ 1 or body surface area ≤ 3 ; patient pain

visual analogue scale (VAS) ≤ 15 ; patient global disease activity VAS ≤ 20 ; Health Assessment Questionnaire Disability Index ≤ 0.5 ; tender enthesal points ≤ 1

(b) Based on pooled data from BE OPTIMAL and BE COMPLETE studies for patients with baseline Leeds Dactylitis Index (LDI) >0 . Dactylitis free state is LDI=0

(c) Based on pooled data from BE OPTIMAL and BE COMPLETE studies for patients with baseline Leeds Enthesitis Index (LEI) >0 . Enthesitis free state is LEI =0

(d) Based on pooled data from BE OPTIMAL and BE COMPLETE studies for patients with baseline Spondyloarthritis Research Consortium of Canada (SPARCC) >0 . Enthesitis free state is SPARCC =0

(e) Unadjusted differences are shown

(f) Secondary endpoint that was not included in the hierarchy

* $p < 0.001$ versus placebo adjusted for multiplicity. ** $p = 0.008$ versus placebo adjusted for multiplicity. *** $p = 0.002$ versus placebo adjusted for multiplicity. NRI is used. Endpoints not in the hierarchy were not subject to statistical testing.

Endpoints/timepoints not labeled as primary or secondary are considered other/exploratory

In BE OPTIMAL, at Week 16, in patients treated with adalimumab (active reference treatment without any statistical comparison to bimekizumab or placebo performed), 45.7%, 41.2% and 45.0% achieved ACR50, PASI 90 and MDA respectively.

Improvements from baseline were shown in all individual ACR components with bimekizumab at Week 16 (see Table 15) and were sustained up to Week 52 in BE OPTIMAL.

Table 15: Mean Change from baseline in ACR components in study BE OPTIMAL and BE COMPLETE


	BE OPTIMAL (bDMARD-naïves)		BE COMPLETE (TNF α -IRs)	
	Placebo (N=281)	BKZ 160 mg Q4W (N=431)	Placebo (N=133)	BKZ 160 mg Q4W (N=267)
Number of swollen joints				
Baseline	9.5	9.0	10.3	9.7
Mean change at Week 16	-3.0	-6.6	-2.0	-7.0
Mean change at Week 52		-7.6		
Number of tender joints				
Baseline	17.1	16.8	19.3	18.4
Mean change at Week 16	-3.2	-10.0	-2.4	-10.9
Mean change at Week 52		-12.5		
Patient's Assessment of Pain				
Baseline	56.8	53.7	61.7	58.3
Mean change at Week 16	-6.2	-23.6	-4.5	-27.7
Mean change at Week 52		-30.4		
Patient Global Assessment				
Baseline	58.6	54.4	63.0	60.5
Mean change at Week 16	-7.7	-26.3	-5.5	-31.8
Mean change at Week 52		-33.2		
Physician Global Assessment				
Baseline	57.3	57.2	57.7	59.3
Mean change at Week 16	-12.5	-37.4	-6.8	-39.4
Mean change at Week 52		-44.9		
Disability Index (HAQ-DI)				
Baseline	0.9	0.8	1.0	1.0
Mean change at Week 16	-0.1	-0.3*	-0.1	-0.4*
Mean change at Week 52		-0.3		
hs-CRP (mg/l)				
Baseline (geometric mean)	4.4	3.7	4.8	4.8
Ratio to Baseline at Week 16	0.9	0.6	1.1	0.5
Mean change at Week 52		0.6		

HAQ-DI = Health Assessment Questionnaire-Disability Index. CRP= C-reactive protein.

Multiple Imputation (MI) is used. * $p < 0.001$ reference-based imputation versus placebo adjusted for multiplicity.


Bimekizumab was associated with a rapid onset of efficacy in both bDMARD-naïve (BE OPTIMAL) and anti-TNF α -IR (BE COMPLETE) patients. In BE OPTIMAL, as early as Week 2 (first post-baseline visit), the ACR 20 response rate was higher in the bimekizumab-treated group (27.1%) compared with the placebo group (7.8%). By Week 4, after one dose, 17.6 % of patients achieved an ACR 50 with bimekizumab compared to 3.2 % with placebo. In BE COMPLETE, after one dose, as early as Week 4 (first post-baseline visit) the ACR 20 and ACR 50 response rates were higher for the bimekizumab-treated group (42.7% and 16.1%, respectively) compared with the placebo group (6.8% and 1.5%, respectively).

Figure 5: ACR 50 response over time up to Week 52 in BE OPTIMAL (NRI)



Patients on placebo switched to bimekizumab 160 mg Q4W at Week 16.

Figure 6: ACR 50 response over time up to Week 16 in BE COMPLETE (NRI)



In BE OPTIMAL, of bimekizumab-treated patients who achieved an ACR 50 response at Week 16, 87.2% maintained this response at Week 52.

In BE OPTIMAL at Week 52, 65.5% of bimekizumab-treated patients achieved complete nail clearance (mNAPSI resolution in patients with mNAPSI >0 at baseline).

The efficacy and safety of bimekizumab was demonstrated regardless of age, gender, race, baseline body weight, baseline psoriasis involvement, baseline CRP, disease duration, and prior cDMARDs use.

In both studies, similar responses were observed with bimekizumab regardless of whether patients were on concomitant cDMARDs, including MTX, or not.

The modified Psoriatic Arthritis Response Criteria (PsARC) is a specific composite responder index comprising of tender joint count, swollen joints count, patient and physician global assessment. The proportion of patients achieving modified PsARC at Week 16 was higher in the bimekizumab-treated patients compared to placebo (80.3% versus 40.2% in BE OPTIMAL and 85.4% versus 30.8% in BE COMPLETE). In addition, the proportion of patients achieving a low disease activity or remission as measured by the Disease Activity Index for Psoriatic Arthritis (DAPSA score less or equal to 14) was higher in the bimekizumab-treated patients compared to placebo in both studies. PsARC response and DAPSA response were sustained up to Week 52 in BE OPTIMAL.

Patients with axial involvement at baseline (74.1% of patients in BE OPTIMAL and 75% in BE COMPLETE), (defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4) showed greater improvement from baseline in BASDAI compared with placebo at Week 16. Improvement achieved at Week 16 was sustained up to Week 52 in BE OPTIMAL.

Radiographic response

In BE OPTIMAL, inhibition of progression of structural damage was assessed radiographically and expressed as the change from baseline in the Van der Heijde modified total Sharp Score (vdHmTSS) (see Table 16) and its components, the Erosion Score (ES) and the Joint Space Narrowing score (JSN) at Week 16 and Week 52.

Table 16: Change in vdHmTSS in BE OPTIMAL

	Placebo	BKZ 160mg Q4W	Difference from placebo (95% CI) ^{a)}
Population with elevated hs-CRP and/or at least 1 bone erosion at baseline	(N=227)	(N=361)	
Mean change from baseline at Week 16 (SE)	0.36 (0.10)	0.04 (0.05)*	-0.32 (-0.35, -0.30)
Mean change from baseline at Week 52 (SE)		0.10 (0.08)	
Overall population	(N=269)	(N=420)	
Mean change from baseline at Week 16 (SE)	0.32 (0.09)	0.04 (0.04)*	-0.26 (-0.29, -0.23)
Mean change from baseline at Week 52 (SE)		0.10 (0.07)	

*p =0.001 versus placebo. p-values are based on reference-based imputation using difference in LS Mean using an ANCOVA model with treatment, bone erosion at Baseline and region as fixed effects and Baseline score as a covariate. Week 16 summary data is based on the first set of reads for the primary analysis. Week 52 summary data is based on the set of reads done at the completion of the study with missing data imputed using multiple imputation.

^{a)} Unadjusted differences are shown

Bimekizumab significantly inhibited the rate of progression of joint damage at Week 16 in both the population with elevated hs-CRP and/or at least 1 bone erosion at baseline and the overall population compared to placebo. The percentage of patients with no radiographic joint damage progression (defined as a change from baseline in mTSS of ≤ 0.5) from randomization to Week 16 was 83.9% for bimekizumab and 77.5% for placebo in the population with elevated hs-CRP and/or at least 1 bone erosion. Similar responses were achieved in the overall population (85.7% for bimekizumab and 78.8% for placebo). The percentage of patients with no radiographic joint damage progression was sustained up to Week 52 with bimekizumab in both patient populations.

Physical function and other health-related outcomes

Both bDMARD-naïve (BE OPTIMAL) and anti-TNF α -IR (BE COMPLETE) patients receiving bimekizumab showed significant improvement from baseline in physical function compared to placebo patients at Week 16 ($p < 0.001$) as assessed by the HAQ-DI (see Table 15). In both studies, a greater proportion of patients achieved a clinically meaningful reduction of at least 0.35 in HAQ-DI score from baseline in the bimekizumab group compared with placebo at Week 16. Response was sustained up to Week 52 in BE OPTIMAL.

Bimekizumab-treated patients reported significant improvement from baseline in the Short Form-36 item Health Survey Physical Component Summary (SF-36 PCS) score at Week 16 compared to placebo (LS Mean change from baseline: 6.3 versus 1.9, $p < 0.001$ in BE OPTIMAL and 6.2 versus 0.1, $p < 0.001$ in BE COMPLETE).

In both studies, bimekizumab-treated patients reported meaningful reduction from baseline in fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score at Week 16 compared to placebo. Meaningful improvement from baseline was also observed in PsA specific health-related quality of life as measured by the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) score in the bimekizumab-treated group compared to the placebo group at Week 16.

Bimekizumab-treated patients reported greater improvement in work productivity and daily activity at Week 16 as reported by the Work Productivity and Activity Impairment Questionnaire-specific health Problem (WPAI-SHP) compared to placebo.

Improvements in HAQ-DI score, SF-36 PCS score, FACIT-Fatigue score, PsAID-12 score and WPAI-SHP achieved at Week 16 were sustained up to Week 52 in BE OPTIMAL.

Axial spondyloarthritis

The efficacy and safety of bimekizumab were evaluated in 586 adult patients (at least 18 years of age) with active axial spondyloarthritis (axSpA) in two multicenter, randomized, double-blind, placebo-controlled studies, one in non-radiographic axial spondyloarthritis (nr-axSpA) and one in ankylosing spondylitis (AS), also known as radiographic axSpA. The primary endpoint in both studies was the percentage of patients achieving an Assessment of SpondyloArthritis International Society (ASAS) 40 response at Week 16. Consistent results were seen across both patient populations (nr-axSpA and AS).

The BE MOBILE 1 study (AS0010) evaluated 254 patients with active nr-axSpA. Patients had axSpA (age of symptoms onset < 45 years) meeting the ASAS classification criteria and had active disease as defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4 and spinal pain ≥ 4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2) and no evidence of radiographic changes in the sacroiliac joints that would meet the modified New York criteria for AS. Patients also had objective signs of inflammation as indicated by elevated C-reactive protein (CRP) level and/or evidence of sacroiliitis on Magnetic Resonance Imaging (MRI) as well as a history of inadequate response to 2 different non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance or contraindication to NSAIDs. Patients were randomized (1:1) to receive bimekizumab 160 mg every 4 weeks up to Week 52 or placebo up to Week 16 followed by bimekizumab 160 mg every 4 weeks up to Week 52. At baseline, patients had symptoms of nr-axSpA for a mean of 9 years (median of 5.5 years). 10.6% of patients were previously treated with an anti-TNF α agent.

The BE MOBILE 2 study (AS0011) evaluated 332 patients with active AS determined by documented radiologic evidence (x-ray) fulfilling the Modified New York criteria for AS. Patients had active disease as defined by a BASDAI ≥ 4 and spinal pain ≥ 4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2). Patients had to have a history of inadequate response to 2 different

NSAIDs or intolerance or contraindication to NSAIDs. Patients were randomized (2:1) to receive bimekizumab 160 mg every 4 weeks up to Week 52 or placebo up to Week 16 followed by bimekizumab 160 mg every 4 weeks up to Week 52. At baseline, patients had symptoms of AS for a mean of 13.5 years (median of 11 years). 16.3% of patients were previously treated with an anti-TNF α agent.

Clinical response

Treatment with bimekizumab resulted in significant improvement in signs and symptoms and measures of disease activity compared to placebo at Week 16 in both nr-axSpA and AS patient populations (see Table 17). Clinical responses were sustained up to Week 52 in both patient populations as assessed by all the endpoints presented in Table 17.

Table 17: Clinical responses in BE MOBILE 1 and BE MOBILE 2

	BE MOBILE 1 (nr-axSpA)			BE MOBILE 2 (AS)		
	Placebo (N=126) n (%)	BKZ 160 mg Q4W (N=128) n (%)	Difference from placebo (95% CI) ^{b)}	Placebo (N=111) n (%)	BKZ 160 mg Q4W (N=221) n (%)	Difference from placebo (95% CI) ^{b)}
ASAS 40 Week 16 (primary) Week 52	27 (21.4)	61 (47.7)* 78 (60.9)	26.2 (14.9, 37.5)	25 (22.5)	99 (44.8)* 129 (58.4)	22.3 (11.5, 33.0)
ASAS 40 in anti-TNFα naives Week 16 (secondary) Week 52	25 (22.9) (N=109)	55 (46.6) (N= 118) 73 (61.9)	24.8 (12.4, 37.1)	22 (23.4) (N=94)	84 (45.7)* (N=184) 108 (58.7)	22.3 (10.5, 34.0)
ASAS 20 Week 16 (secondary) Week 52	48 (38.1)	88 (68.8)* 94 (73.4)	30.7 (19.0, 42.3)	48 (43.2)	146 (66.1)* 158 (71.5)	22.8 (11.8, 33.8)
ASAS 5/6 Week 16 (secondary) Week 52	26 (20.6)	58 (45.3)* 71 (55.5)	24.7 (13.5, 35.9)	21 (18.9)	109 (49.3)* 124 (56.1)	30.4 (19.8, 41.0)
ASAS-partial remission Week 16 (secondary) Week 52	9 (7.1)	33 (25.8)* 38 (29.7)	18.6 (9.7, 27.6)	8 (7.2)	53 (24.0)* 66 (29.9)	16.8 (8.1, 25.5)
ASDAS-major improvement Week 16 (secondary) Week 52	9 (7.1)	35 (27.3)* 47 (36.7)	20.2 (11.2, 29.3)	6 (5.4)	57 (25.8)* 71 (32.1)	20.4 (11.7, 29.1)
ASDAS <2.1^{a)} Week 16 Week 52	25 (19.8)	59 (46.1) 69 (53.9)	26.3 (15.1, 37.4)	19 (17.1)	93 (42.1) 111 (50.2)	25.0 (14.5, 35.4)
BASDAI-50 Week 16 Week 52	27 (21.4)	60 (46.9) 69 (53.9)	25.3 (14.0, 36.6)	29 (26.1)	103 (46.6) 119 (53.8)	20.5 (9.6, 31.4)

BKZ 160 mg Q4W = bimekizumab 160 mg every 4 weeks. ASDAS = Ankylosing Spondylitis Disease Activity Score.

^{a)} ASDAS <2.1 includes ASDAS \geq 1.3, <2.1 (low disease activity) and ASDAS <1.3 (inactive disease).

NRI is used.

*p<0.001 versus placebo, adjusted for multiplicity. Endpoints not in the hierarchy were not subject to statistical testing. Endpoints/timepoints not labeled as primary or secondary are considered other/exploratory^{b)} Unadjusted differences are shown.

Improvements in the components of the ASAS 40 response criteria and other measures of efficacy are shown in Table 18. Improvements achieved at Week 16 were sustained up to Week 52 in both patient populations.

Table 18: ASAS 40 components and other measures of efficacy in BE MOBILE 1 and BE MOBILE 2

	BE MOBILE 1 (nr-axSpA)		BE MOBILE 2 (AS)	
	Placebo (N= 126)	BKZ 160 mg Q4W (N= 128)	Placebo (N= 111)	BKZ 160 mg Q4W (N=221)
ASAS components				
- PGADA				
Baseline	6.9	7.1	6.7	6.6
Mean change from baseline at Week 16	-1.4	-3.2	-1.6	-2.7
Mean change from baseline at Week 52		-4.1		-3.6
- Total spinal pain				
Baseline	7.1	7.3	7.2	7.1
Mean change from baseline at Week 16	-1.7	-3.4	-1.9	-3.3
Mean change from baseline at Week 52		-4.2		-4.1
- BASFI (secondary)				
Baseline	5.3	5.5	5.2	5.3
Mean change from baseline at Week 16	-1.0	-2.5*	-1.1	-2.2*
Mean change from baseline at Week 52		-3.6		-2.8
- Inflammation (BASDAI 5&6)				
Baseline	6.9	7.0	6.8	6.7
Mean change from baseline at Week 16	-1.9	-3.6	-2.1	-3.2
Mean change from baseline at Week 52		-3.0		-3.9
Nocturnal spinal pain (secondary)				
Baseline	6.7	6.9	6.8	6.6
Mean change from baseline at Week 16	-1.7	-3.6*	-1.9	-3.3*
Mean change from baseline at Week 52		-4.3		-4.1
ASDAS-CRP				
Baseline	3.7	3.8	3.7	3.7
Mean change from baseline at Week 16	-0.6	-1.5	-0.7	-1.4
Mean change from baseline at Week 52		-1.8		-1.7
BASDAI (secondary)				
Baseline	6.7	6.9	6.5	6.5
Mean change from baseline at Week 16	-1.5	-3.1*	-1.9	-2.9*
Mean change from baseline at Week 52		-3.9		-3.6
BASMI (secondary)				
Baseline	3.0	2.9	3.8	3.9
Mean change from baseline at Week 16	-0.1	-0.4	-0.2	-0.5**
Mean change from baseline at Week 52		-0.6		-0.7
hs-CRP (mg/L)				
Baseline (Geometric Mean)	5.0	4.6	6.7	6.5
Ratio to Baseline at Week 16	0.8	0.4	0.9	0.4
Ratio to Baseline at Week 52		0.4		0.3

PGADA = Patient's Global Assessment of Disease Activity. BASFI = Bath Ankylosing Spondylitis Functional Index. BASMI = Bath Ankylosing Spondylitis Metrology Index. Hs-CRP = high sensitivity C-reactive protein MI is used.


*p<0.001 reference based imputation versus placebo, adjusted for multiplicity. **p<0.01 reference based imputation versus placebo, adjusted for multiplicity. Endpoints not in the hierarchy were not subject to statistical testing. Endpoints/timepoints not labeled as primary or secondary are considered other/exploratory

Bimekizumab was associated with a rapid onset of efficacy in both nr-axSpA and AS patient population.

In BE MOBILE 1, as early as Week 1, the ASAS 20 and ASAS 40 response rates in bimekizumab-treated patients were greater than in placebo-treated patients (31.3% versus 11.9% and 16.4% versus 1.6%, respectively). Bimekizumab was also associated with a rapid decrease in systemic inflammation as measured by the hs-CRP levels. As early as Week 2 (first measurement of hs-CRP), the geometric mean hs-CRP ratio to baseline was lower in the bimekizumab-treated patients (0.4) compared to placebo (0.9).


In BE MOBILE 2, as early as Week 2, the ASAS 20 and ASAS 40 response rates in bimekizumab-treated patients were greater than in placebo-treated patients (43.4% versus 25.2% and 16.7% versus 7.2% respectively). Bimekizumab was also associated with a rapid decrease in systemic inflammation as measured by hs-CRP levels. As early as Week 2 (first measurement of hs-CRP), the geometric mean hs-CRP ratio to baseline was lower in the bimekizumab-treated patients (0.4) compared to placebo (0.9).

Figure 7: ASAS 40 response over time up to Week 52 in BE MOBILE 1 (NRI)



Patients on placebo switched to bimekizumab 160 mg Q4W at Week 16

Figure 8: ASAS 40 response over time up to Week 52 in BE MOBILE 2 (NRI)



Patients on placebo switched to bimekizumab 160 mg Q4W at Week 16

In an integrated analysis of BE MOBILE 1 and BE MOBILE 2, of bimekizumab-treated patients who achieved an ASAS 40 response at Week 16, 82.1% maintained this response at Week 52.

The efficacy of bimekizumab was demonstrated regardless of age, gender, race, disease duration, baseline inflammation status, baseline ASDAS and concomitant cDMARDs. Patients with a BMI $\geq 30\text{kg/m}^2$ may take longer time to achieve clinical response.

Similar response in ASAS 40 was seen in patients regardless of prior anti-TNF α exposure.

At Week 16, among patients with enthesitis at baseline, the proportion of patients (NRI) with enthesitis resolution as assessed by the Maastricht Ankylosing Spondylitis Enthesitis (MASES) index was greater with bimekizumab compared to placebo (BE MOBILE 1: 51.1% versus 23.9% and BE MOBILE 2: 51.5% versus 32.8%). Response with bimekizumab was sustained up to Week 52 in both studies (BE MOBILE 1: 54.3% and BE MOBILE 2: 50.8%).

Reduction of inflammation

Bimekizumab reduced inflammation as measured by hs-CRP (see Table 18) and as assessed by MRI in an imaging sub-study. Signs of inflammation were assessed by MRI at baseline and Week 16 and expressed as change from baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) score for sacroiliac joints and Ankylosing Spondylitis spine Magnetic Resonance Imagine-activity (ASspiMRI-a score in the Berlin modification) for the spine. Reduction of inflammatory signs in both sacroiliac joints and the spine was observed in patients treated with bimekizumab as compared with placebo (see Table 19). Reduction of inflammation as measured by hs-CRP and as assessed by MRI was sustained to Week 52.

Table 19: Reduction of inflammation as assessed by MRI in BE MOBILE 1 and BE MOBILE 2

	BE MOBILE 1 (nr-axSpA)		BE MOBILE 2 (AS)	
	Placebo	BKZ 160 mg Q4W	Placebo	BKZ 160 mg Q4W
SPARCC score Mean change from baseline ^{a)} at Week 16	-1.56 (N=62)	-6.15 (N=78)	0.59 (N=46)	-4.51 (N=81)
Mean change from baseline ^{a)} at Week 52		-7.57 (N=67)		-4.67 (N=78)
ASspiMRI-a (Berlin modifications) score				
Mean change from baseline ^{a)} at Week 16	0.03 (N=60)	-0.36 (N=74)	-0.34 (N=46)	-2.23 (N=81)
Mean change from baseline ^{a)} at Week 52		-0.70 (N=65)		-2.38 (N=77)

^{a)} Change from baseline values are based on observed cases.

Physical function and other health-related outcomes

Patients treated with bimekizumab showed significant improvement from baseline in physical function as assessed by the BASFI (see Table 18). Patients treated with bimekizumab reported significant improvement from baseline compared to placebo-treated patients in SF-36 PCS score (LS Mean change from baseline at Week 16 in BE MOBILE 1: 9.3 versus 5.4, $p < 0.001$ and in BE MOBILE 2: 8.5 versus 5.2, $p < 0.001$).

Patients treated with bimekizumab reported significant improvement from baseline in health-related quality of life as measured by the AS Quality of Life Questionnaire (ASQoL) compared to placebo (LS Mean change from baseline at Week 16 in BE MOBILE 1: -4.9 versus -2.3, $p < 0.001$ and in BE MOBILE 2: -4.6 versus -3.0, $p < 0.001$) as well as meaningful reduction in fatigue as assessed by the FACIT-Fatigue score (Mean change from baseline at Week 16 in BE MOBILE 1: 8.5 for bimekizumab versus 3.9 for placebo and in BE MOBILE 2: 8.4 for bimekizumab versus 5.0 for placebo).

Bimekizumab-treated patients reported greater improvement in work productivity and daily activities at Week 16 as reported by the WPAI-SHP compared to placebo.

Improvements in BASFI, SF-36 PCS score, ASQoL, FACIT-Fatigue score and WPAI-SHP achieved at Week 16 were sustained up to Week 52 in both studies.

Extra-articular manifestation

In pooled data from BE MOBILE 1 (nr-axSpA) and BE MOBILE 2 (AS), at Week 16, the proportion of patients developing a uveitis event was lower with bimekizumab (0.6%) compared to placebo (4.6%). The incidence of uveitis remains low in bimekizumab-treated patients (1.2/100 patient-years in the pooled phase 2/3 studies).

Hidradenitis suppurativa

The safety and efficacy of bimekizumab was evaluated in 1014 adult patients (at least 18 years of age) with moderate to severe Hidradenitis Suppurativa (HS) in two Phase 3 multicenter, randomized, double-blind, placebo-controlled studies (HS0003 – BE HEARD I and HS0004 – BE HEARD II). Patients had a diagnosis of HS for at least 6 months with Hurley Stage II or Hurley Stage III disease, and with ≥ 5 inflammatory lesions (i.e. number of abscesses plus number of inflammatory nodules) and had a history of inadequate response to a course of systemic antibiotics for the treatment of HS.

In both studies patients were randomized (2:2:2:1) to receive bimekizumab 320 mg every 2 weeks for 48 weeks (320 mg Q2W/Q2W) or bimekizumab 320 mg every 4 weeks for 48 weeks (320 mg Q4W/Q4W) or bimekizumab 320 mg every 2 weeks to Week 16 followed by 320 mg every 4 weeks up to Week 48 (320 mg Q2W/Q4W) or placebo to Week 16 followed by bimekizumab 320 mg every 2 weeks up to Week 48. Concomitant oral antibiotic use was allowed if the patient was on a stable dose regimen of doxycycline, minocycline, or an equivalent systemic tetracycline for 28 days prior to baseline.

The primary efficacy endpoint in both studies was the Hidradenitis Suppurativa Clinical Response 50 (HiSCR₅₀) at Week 16, i.e. at least a 50% reduction in the total abscess and inflammatory nodule count with no increase in abscess or draining tunnel count relative to baseline.

Baseline characteristics were consistent across both studies and reflective of a population with moderate to severe HS. Patients had a median disease duration of 5.3 years (mean 8.0 years). The proportions of Hurley Stage II and Stage III patients were 55.7% and 44.3% respectively, and 8.5% were receiving concomitant antibiotic therapy for HS. 56.8% of patients were female and the mean age of all patients was 36.6 years. 79.7% of patients were White, and 10.8% were Black or African American. 45.6% of patients were current smokers.

The mean International Hidradenitis Suppurativa Severity Score System (IHS4) score was 34.2 indicating severe disease. The mean baseline Abscess and Inflammatory Nodule (AN) Count was 16.3, the mean baseline worst skin pain score was 5.5 and the mean baseline total Hidradenitis suppurativa Quality of Life (HiSQOL) and total Dermatology Life Quality Index (DLQI) scores were 25.2 and 11.4, respectively.

Clinical response

Treatment with bimekizumab resulted in improvement in disease activity compared to placebo at Week 16. Key efficacy results are shown in Table 20. The results in Table 20 reflect the predefined primary analysis in which any systemic antibiotic use prior to Week 16 resulted in imputation of nonresponse.

Table 20: Response in BE HEARD I and BE HEARD II at Week 16 - primary analysis^{a)}

	BE HEARD I			BE HEARD II		
	Placebo (N=72)	BKZ 320 mg Q4W (N=144)	BKZ 320 mg Q2W (N=289)	Placebo (N=74)	BKZ 320 mg Q4W (N=144)	BKZ 320 mg Q2W (N=291)
HiSCR ₅₀ , %	28.7	45.3	47.8*	32.2	53.8*	52.0*
HiSCR ₇₅ , %	18.4	24.7	33.4*	15.6	33.7*	35.7*
HSSDD worst skin pain response ^{b)} %	15.0	22.1	32.3	10.9	28.6	31.8


^{a)} Patients who take systemic antibiotics for any reason or who discontinue due to adverse event or lack of efficacy are treated as non-responders at all subsequent visits for responder variables (or are subject to multiple imputation for continuous variables). Other missing data were imputed via multiple imputation.

^{b)} Skin pain response, based on the threshold for within-patient clinically meaningful change (defined as at least a 3-point decrease from Baseline in Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) weekly worst skin pain score) at Week 16 among study participants with a score of ≥ 3 at Baseline. For BE HEARD I: N=46 for placebo, N=103 for BKZ Q4W and N=190 for BKZ Q2W; BE HEARD II: N=49 for placebo, N=108 for BKZ Q4W and N=209 for BKZ Q2W.

*p<0.025 versus placebo, adjusted for multiplicity.

At Week 4, HiSCR₅₀ response rates were higher for bimekizumab-treated patients (36.5 % and 35.1%) compared to placebo (18.1% and 22.2 %) in BE HEARD I and BE HEARD II, respectively. Improvement in patients reporting worst skin pain response as measured by the HSSDD started at Week 2.


Figure 9: HiSCR₅₀ response over time to Week 48 in BE HEARD I



Patients on placebo switched to bimekizumab at Week 16.

mNRI (modified nonresponder imputation): Patients who take systemic antibiotics as rescue medication for HS as defined by the investigator or who discontinue due to adverse event or lack of efficacy are treated as non-responders at all subsequent visits. Other missing data were imputed via multiple imputation.

Figure 10: HiSCR₅₀ response over time to Week 48 in BE HEARD II



Patients on placebo switched to bimekizumab at Week 16.

mNRI (modified nonresponder imputation): Patients who take systemic antibiotics as rescue medication for HS as defined by the investigator or who discontinue due to adverse event or lack of efficacy are treated as non-responders at all subsequent visits. Other missing data were imputed via multiple imputation.

Consistent with the HiSCR₅₀ response rates, the $\geq 50\%$ reduction in the total abscess and inflammatory nodule (AN₅₀) count responder rates at Week 16 were higher in the bimekizumab-treated patients (320 mg every 2 weeks) compared to placebo (51.8% versus 34.7% in BE HEARD I and 58.1% versus 39.0% in BE HEARD II). Responses were sustained up to Week 48 with bimekizumab 320 mg every 4 weeks.

The efficacy of bimekizumab was demonstrated regardless of age, gender, race, disease duration, weight, prior biologics therapy and systemic antibiotic use at baseline.

Health-related quality of life

Across both studies, patients treated with bimekizumab experienced greater improvement in their health-related quality of life as measured by DLQI questionnaire compared to placebo (Table 21).

Table 21: Health-related quality of life in BE HEARD I and BE HEARD II at Week 16

	BE HEARD I			BE HEARD II		
	Placebo (N=72)	BKZ 320 mg Q4W (N=144)	BKZ 320 mg Q2W (N=289)	Placebo (N=74)	BKZ 320 mg Q4W (N=144)	BKZ 320 mg Q2W (N=291)
DLQI total score Mean cfb ^{a)} (SE)	-2.9 (0.8)	-5.4 (0.6)	-5.0 (0.4)	-3.2 (0.6)	-4.5 (0.5)	-4.6 (0.3)

DLQI total score ranges from 0 to 30 with higher scores indicating lower HRQoL.

^{a)} cfb: change from baseline

Improvement achieved at Week 16 in health-related quality of life measurements with bimekizumab were sustained through Week 48.

5.2 PHARMACOKINETIC PROPERTIES

The pharmacokinetic (PK) properties of bimekizumab were similar in patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis (nr-axSpA and AS). Based on population PK analyses and using a reference bodyweight of 90 kg, the bimekizumab apparent clearance and volume of distribution, respectively, in patients with HS were estimated to be approximately 31 and 18 % higher than for the aforementioned indications, with an estimated half-life in HS of 20 days. Consequently, the median steady state trough concentration at a dose of 320 mg every 4 weeks was approximately 40 % lower in HS compared to other indications.

Bimekizumab exhibited dose-proportional pharmacokinetics in patients with plaque psoriasis over a dose range from 64 mg to 480 mg following multiple subcutaneous administrations, with apparent clearance being independent of dose.

Absorption

Based on population PK analysis, following a single subcutaneous dose of 320 mg in plaque psoriasis patients, bimekizumab reached a median (2.5th and 97.5th percentile) peak plasma concentration of 25 (12 -50) µg/ml, between 3 and 4 days post dose.

Population pharmacokinetic analysis showed that bimekizumab was absorbed with an average absolute bioavailability of 70.1% in healthy volunteers.

Distribution

Based on population PK analyses, the median (coefficient of variation %) volume of distribution (V/F) at steady state was 11.2 (30.5%) L in plaque psoriasis patients.

Metabolism

Bimekizumab is a monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous immunoglobulins.

Excretion

Based on population PK analyses, the median (coefficient of variation %) apparent clearance (CL/F) of bimekizumab was 0.337 L/day (32.7%) and the mean terminal elimination half-life of bimekizumab was 23 days in clinical studies in patients with plaque psoriasis.

Based on simulated data, the median (2.5th and 97.5th percentile) peak and trough concentration at steady-state following subcutaneous administration of 320 mg every 4 weeks are 43 (20-91) µg/ml and 20 (7-50) µg/ml respectively and steady-state is reached after approximately 16 weeks with every 4 weeks dosing regimen. Compared with exposure after a single dose, the population PK analysis showed that patients exhibited a 1.74-fold increase in peak plasma concentrations and area under the curve (AUC) following repeated four weekly dosing.

After switching from the 320 mg every 4 weeks dosing regimen to 320 mg every 8 weeks dosing regimen at Week 16, steady-state is achieved approximately 16 weeks after the switch. Median (2.5th and 97.5th percentile) peak and trough plasma concentrations are 30 (14 -60) µg/ml and 5 (1-16) µg/ml respectively.

Pharmacokinetic/pharmacodynamic relationship

A population PK/PD model was developed using all available data in moderate to severe plaque psoriasis patients. The analysis showed that higher bimekizumab concentrations are related to better Psoriasis Area and Severity Index (PASI) and Investigators Global Assessment (IGA) response and a dose of 320 mg at Week 0, 4, 8, 12, 16 and every 8 weeks thereafter provides maximum benefit to the majority of moderate to severe plaque psoriasis patients (see special population, body weight).

Special populations

Elderly

Based on population PK analysis with a limited number of elderly patients (n = 355 for age \geq 65 years and n = 47 for age \geq 75 years), apparent clearance (CL/F) in elderly patients and patients less than 65 years of age was similar. No dose adjustment is required.

Renal or hepatic impairment

No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of bimekizumab. Caution should be taken in people with hepatic and renal dysfunction, due to the absence of data from these populations in the studies. The renal elimination of intact bimekizumab, an IgG monoclonal antibody, is expected to be low and of minor importance. Similarly, IgGs are mainly eliminated via intracellular catabolism and hepatic impairment is not expected to influence clearance of bimekizumab. Based on population PK analyses, hepatic function markers (ALT/ bilirubin) did not have any impact on bimekizumab clearance in patients with plaque psoriasis.

Body weight

Population PK modelling indicated that exposure decreased as body weight increased. The average plasma concentration in adult patients weighing \geq 120 kg following a 320 mg subcutaneous injection was predicted to be at least 30% lower than in adult patients weighing 90 kg. Dose adjustment may be appropriate in some patients (see section 4.2 Dose and method of administration).

Race / Gender

No clinically meaningful differences in bimekizumab exposure were observed in Japanese or Chinese subjects compared to Caucasian subjects in a clinical PK study. No dose adjustment is required.

Population PK modelling indicated females may have 10% faster apparent clearance (CL/F) compared to males and it is not clinically meaningful. No dose adjustment is required.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

No genotoxicity studies were conducted with bimekizumab. Monoclonal antibodies are not expected to damage DNA or chromosomes.

Carcinogenicity

No carcinogenicity studies were conducted with bimekizumab.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

The inactive ingredients are glycine, sodium acetate trihydrate, acetic acid, polysorbate 80, water for injections.

6.2 INCOMPATIBILITIES

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 SHELF LIFE

36 months.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Keep the pre-filled syringe or pen in the outer carton in order to protect from light.

The Bimzelx pre-filled syringe and pre-filled pen may be stored at room temperature (up to 25°C) for a single period of maximum 30 days with protection from light. Once removed from the refrigerator and stored under these conditions, discard after 30 days or by the expiry date printed on the container, whichever occurs first. A field for the date is provided on the carton to record the date removed from the refrigerator.

6.5 NATURE AND CONTENTS OF CONTAINER

Bimzelx 160 mg solution for injection in pre-filled syringe.

One ml pre-filled syringe (type I glass) with a fluoropolymer-laminated bromobutyl rubber stopper, staked 27G, ½” thin wall needle, and a rigid needle shield (consisting of a thermoplastic elastomer needle cover and a polypropylene rigid shield) assembled in a passive safety device.

Pack size of 2 pre-filled syringes.

Bimzelx 320 mg solution for injection in pre-filled syringe.

Two ml pre-filled syringe (type I glass) with a fluoropolymer-laminated bromobutyl rubber stopper, staked 27G, ½” thin wall needle, and a rigid needle shield (consisting of a thermoplastic elastomer needle cover and a polypropylene rigid shield) assembled in a passive safety device.

Pack size of 1 pre-filled syringe.

Bimzelx 160 mg solution for injections in pre-filled pen.

One ml pre-filled pen containing a pre-filled syringe (type I glass) with a fluoropolymer-laminated bromobutyl rubber stopper, staked 27G, ½” thin wall needle, and a rigid needle shield consisting of a thermoplastic elastomer needle cover and a polypropylene rigid shield..

Pack size of 2 pre-filled pens.

Bimzelx 320 mg solution for injection in pre-filled pen.

Two ml pre-filled pen containing a pre-filled syringe (type I glass) with a fluoropolymer-laminated bromobutyl rubber stopper, staked 27G, ½” thin wall needle, and a rigid needle shield consisting of a thermoplastic elastomer needle cover and a polypropylene rigid shield.

Pack size of 1 pre-filled pen.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.


6.7 PHYSICOCHEMICAL PROPERTIES

Chemical Name: Immunoglobulin G1, anti-IL17A and anti-IL17F

Nominal theoretical molecular mass: approximately 149,886 Da^a

^aTheoretical mass based on presence of G0F glycans and clipped heavy chain C-terminal modifications

Chemical structure



CAS number

1418205-77-2

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4

8 SPONSOR

UCB Pharma

A division of UCB Australia Pty Ltd

Level 1, 1155 Malvern Road

Malvern VIC 3144, Australia

Phone: +613 9828 1800

Website: www.ucbaustralia.com.au

E-mail: ucbcares.au@ucb.com

9 DATE OF FIRST APPROVAL

24 March 2022

10 DATE OF REVISION

08 April 2025

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
5.1	Addition of open label extension study data in PSO
4.1, 4.2, 4.5, 4.8, 5.1, 5.2	Extension of indications – hidradenitis suppurativa
2, 4.2	Addition of 2 mL syringe